/Investor DB

Cambridge Innovation Capital — 2026 Investments

2 investments dated 2026 · listed companies and verified rows first · show all

Immutrinimmutrin.cominSeries A · Mar 2026 · $87M✓ verified

Immutrin is a biotechnology company developing antibody therapies designed to remove systemic amyloid deposits and reverse amyloidosis.

BiotechMedical Devices

Mark Pepys(Co-founder; Emeritus Professor of Medicine at UCL)Gregory Winter(Co-founder; Nobel Laureate)Daniel Christ(Co-founder; Professor, Faculty of Medicine, UNSW)

Co-investorsFrazier Life SciencesQiming Venture PartnersF-Prime CapitalSR One Capital Management

Trent AItrent.aiSeed · Apr 2026 · $13M

Trent is an AI security engineer that maps an organization's software, services, and AI agents to reveal the real attack surface, triages vulnerabilities from existing security tools down to what is exploitable, and generates remediation recommendations with a full audit trail.

AI & Machine LearningCybersecurityEnterprise SoftwareGent, BE

Neil Lawrence(Founder)in

Co-investorsLocalGlobePhoenix Court

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.